Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent Chemotherapy and Radiation Therapy for Stage I/II Nasal NK Cell Lymphoma
NCT02106988Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Jan 2034
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dexamethasone, etoposide phosphate, ifosfamide, carboplatin in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by University of Texas MD Anderson Cancer Center. Started Jan 2015; status: active, not recruiting.
02
Drugs
dexamethasoneetoposide phosphateifosfamidecarboplatin
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02106988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106988.